KK2269 is a bispecific antibody targeting CD40 and EpCAM1,2
KK2269 is an EpCAM driven, local-acting CD40 agonist1
- CD40 is a key molecule expressed on APCs, whose signaling activates APCs and generates antitumor immune responses
- EpCAM is overexpressed in many types of epithelial cancers
- KK2269 is a bsAb with binding sites for CD40 and EpCAM designed to selectively activate CD40+ APCs at EpCAM+ tumor sites to avoid systemic toxicities seen with previously investigated CD40 agonists
REGULGENTTM technology2
- REGULGENTTM is a novel symmetric bsAb, comprising 2 Fab domains, using a common light chain to simplify design and production, addressing challenges such as heterogeneity and aggregation associated with bsAb manufacturing
- KK2269 is a C-terminal type REGULGENTTM
Proprietary bispecific antibody technology.
APC, antigen presenting cell; bsAb, bispecific antibody; CD40, Cluster of Differentiation 40; EpCAM, epithelial cell adhesion molecule; Fab, fragment antigen-binding.
References: 1. Tezuka Y et al. Cancer Res. 2024;84 6(Supp):5310. 2. Saito S et al. Protein Sci. 2024;33(10):e5121.